

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
080 FIBRINOGEN		CLIA TEST ID #: 825	EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-161	73 ACL 8 TO E	87 HEMOSIL-C		11	155.273	7.034	4.53	124.000	186.000
2024-161	79 CS-2500	67 DADE		17	139.529	7.349	5.27	112.000	167.000
2024-162	73 ACL 8 TO E	87 HEMOSIL-C		11	290.273	31.305	10.78	232.000	348.000
2024-162	79 CS-2500	67 DADE		17	255.588	10.279	4.02	204.000	307.000
2024-163	73 ACL 8 TO E	87 HEMOSIL-C		11	252.818	20.386	8.06	202.000	303.000
2024-163	79 CS-2500	67 DADE		17	227.176	9.550	4.20	182.000	273.000
2024-164	73 ACL 8 TO E	87 HEMOSIL-C		11	301.636	29.426	9.76	241.000	362.000
2024-164	79 CS-2500	67 DADE		17	259.471	12.045	4.64	208.000	311.000
2024-165	73 ACL 8 TO E	87 HEMOSIL-C		11	604.818	67.992	11.24	484.000	726.000
2024-165	79 CS-2500	67 DADE		17	468.353	38.955	8.32	375.000	562.000
081 PART.THROM. TIME-PTT		CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE 15 %						
2024-161	62 DADE SYS.	35 DADE ACTIN		61	30.156	1.310	4.34	25.600	34.700
2024-161	69 DIAG.STAGO	49 STA-PTT		20	35.695	1.127	3.16	30.300	41.000
2024-161	73 ACL 8 TO E	56 PTT-HEMO		33	30.533	0.379	1.24	26.000	35.100
2024-161	76 STAGO STAR	49 STA-PTT		23	34.865	1.795	5.15	29.600	40.100
2024-161	79 CS-2500	35 DADE ACTIN		17	32.218	1.347	4.18	27.400	37.100
2024-162	62 DADE SYS.	35 DADE ACTIN		61	45.878	2.366	5.16	39.000	52.800
2024-162	69 DIAG.STAGO	49 STA-PTT		20	52.665	2.057	3.91	44.800	60.600
2024-162	73 ACL 8 TO E	56 PTT-HEMO		33	48.573	0.823	1.69	41.300	55.900
2024-162	76 STAGO STAR	49 STA-PTT		23	50.496	2.373	4.70	42.900	58.100
2024-162	79 CS-2500	35 DADE ACTIN		17	49.465	2.195	4.44	42.000	56.900
2024-163	62 DADE SYS.	35 DADE ACTIN		61	26.459	0.781	2.95	22.500	30.400

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-163	69	DIAG.STAGO	49 STA-PTT	20	29.565	0.730	2.47	25.100	34.000		
2024-163	73	ACL 8 TO E	56 PTT-HEMO	33	29.661	0.491	1.66	25.200	34.100		
2024-163	76	STAGO STAR	49 STA-PTT	23	28.377	0.955	3.36	24.100	32.600		
2024-163	79	CS-2500	35 DADE ACTIN	17	27.665	0.525	1.90	23.500	31.800		
081	PART.THROM. TIME-PTT		CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE 15 %							
2024-164	62	DADE SYS.	35 DADE ACTIN	61	37.095	1.307	3.52	31.500	42.700		
2024-164	69	DIAG.STAGO	49 STA-PTT	20	42.080	1.251	2.97	35.800	48.400		
2024-164	73	ACL 8 TO E	56 PTT-HEMO	33	41.406	0.727	1.76	35.200	47.600		
2024-164	76	STAGO STAR	49 STA-PTT	23	41.235	2.253	5.46	35.000	47.400		
2024-164	79	CS-2500	35 DADE ACTIN	17	39.476	1.407	3.56	33.600	45.400		
2024-165	62	DADE SYS.	35 DADE ACTIN	61	26.339	0.763	2.90	22.400	30.300		
2024-165	69	DIAG.STAGO	49 STA-PTT	20	29.905	0.896	3.00	25.400	34.400		
2024-165	73	ACL 8 TO E	56 PTT-HEMO	33	38.585	1.114	2.89	32.800	44.400		
2024-165	76	STAGO STAR	49 STA-PTT	23	28.752	1.385	4.82	24.400	33.100		
2024-165	79	CS-2500	35 DADE ACTIN	17	27.071	0.414	1.53	23.000	31.100		
082	PROTHROMBIN TIME(PT)		CLIA TEST ID #: 845								
2024-161	62	DADE SYS.	33 DADE INNOV	60	12.707	0.445	3.50	10.800	14.600		
2024-161	62	DADE SYS.	33 DADE INNOV	60	18.150	0.180	0.99	15.400	20.900		
2024-161	73	ACL 8 TO E	41 HEMOSIL RE	29	14.390	0.413	2.87	12.200	16.500		
2024-161	76	STAGO STAR	44 STA NEO CI	15	15.753	0.687	4.36	13.400	18.100		
2024-161	79	CS-2500	33 DADE INNOV	18	13.256	0.277	2.09	11.300	15.200		
2024-162	62	DADE SYS.	33 DADE INNOV	60	37.350	0.986	2.64	31.700	43.000		
2024-162	62	DADE SYS.	33 DADE INNOV	60	26.116	1.210	4.63	22.200	30.000		
2024-162	73	ACL 8 TO E	41 HEMOSIL RE	29	33.457	1.431	4.28	28.400	38.500		
2024-162	76	STAGO STAR	44 STA NEO CI	15	34.493	1.650	4.78	29.300	39.700		
2024-162	79	CS-2500	33 DADE INNOV	18	26.217	0.389	1.48	22.300	30.100		
2024-163	62	DADE SYS.	33 DADE INNOV	60	10.281	0.268	2.61	8.700	11.800		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-163	62 DADE SYS.	33 DADE INNOV		60	13.500	0.245	1.81	11.500	15.500	
2024-163	73 ACL 8 TO E	41 HEMOSIL RE		29	10.921	0.204	1.87	9.300	12.600	
2024-163	76 STAGO STAR	44 STA NEO CI		15	12.533	0.411	3.28	10.700	14.400	
2024-163	79 CS-2500	33 DADE INNOV		18	10.811	0.141	1.30	9.200	12.400	
082 PROTHROMBIN TIME(PT)		CLIA TEST ID #: 845		EVALUATION CRITERIA: TARGET VALUE 15 %						
2024-164	62 DADE SYS.	33 DADE INNOV		60	23.075	0.268	1.16	19.600	26.500	
2024-164	62 DADE SYS.	33 DADE INNOV		60	17.338	0.628	3.62	14.700	19.900	
2024-164	73 ACL 8 TO E	41 HEMOSIL RE		29	20.800	0.650	3.12	17.700	23.900	
2024-164	76 STAGO STAR	44 STA NEO CI		15	21.773	0.819	3.76	18.500	25.000	
2024-164	79 CS-2500	33 DADE INNOV		18	17.656	0.142	0.81	15.000	20.300	
2024-165	62 DADE SYS.	33 DADE INNOV		60	10.250	0.265	2.59	8.700	11.800	
2024-165	62 DADE SYS.	33 DADE INNOV		60	13.525	0.455	3.36	11.500	15.600	
2024-165	73 ACL 8 TO E	41 HEMOSIL RE		29	10.866	0.234	2.15	9.200	12.500	
2024-165	76 STAGO STAR	44 STA NEO CI		15	12.673	0.332	2.62	10.800	14.600	
2024-165	79 CS-2500	33 DADE INNOV		18	10.739	0.203	1.89	9.100	12.300	

**Participant Summary**  
**MONTH 3 OF YEAR 2024**

SPE: 20 HEMATOLOGY		SUB: 70 GENERAL			GRP: 100 HEMA. CELL IDENTIFI.						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
072 HEMA. CELL IDENTIFI.											
2024-111					006	006	011 - HYPERSEGME	915	9	904	0
2024-111					006	006	013 - LYMPHOCYTE	915	1	904	0
2024-111					006	006	005 - BAND (STAB	915	1	904	0
2024-111					006	006	006 - SEGMENTED	915	904	904	100
2024-112					041	041	041 - ACANTHOCYT	915	913	913	100
2024-112					041	041	049 - FRAGMENTED	915	2	913	0
2024-113					018	018	014 - LYMPHOCYTE	915	1	913	0
2024-113					018	018	018 - PLATELETS,	915	913	913	100
2024-113					018	018	054 - TARGET CEL	915	1	913	0
2024-114					014	014	013 - LYMPHOCYTE	915	12	896	0
2024-114					014	014	001 - BLAST	915	1	896	0
2024-114					014	014	014 - LYMPHOCYTE	915	896	896	100
2024-114					014	014	017 - MONOCYTE	915	5	896	0
2024-114					014	014	018 - PLATELETS,	915	1	896	0
2024-115					054	054	018 - PLATELETS,	916	1	915	0
2024-115					054	054	054 - TARGET CEL	916	915	915	100

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 137 RETICULOCYTE COUNT						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
149	RETICULOCYTE COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{GREATER}				
2024-141	7	M.B.MANUAL		12	4.636	0.914	19.71	1.900	7.400	
2024-141	24	Unicel DxH		18	3.511	0.294	8.38	2.600	4.400	
2024-141	25	SYSMEX XN		30	1.167	0.404	34.66	0.000	2.400	
2024-142	7	M.B.MANUAL		12	9.917	2.842	28.65	1.400	18.400	
2024-142	24	Unicel DxH		18	7.571	0.397	5.24	5.700	9.500	
2024-142	25	SYSMEX XN		30	2.040	1.090	53.42	0	5.300	
2024-143	7	M.B.MANUAL		12	1.542	0.618	40.11	0	3.400	
2024-143	24	Unicel DxH		18	0.711	0.124	17.47	0.300	1.100	
2024-143	25	SYSMEX XN		30	0.573	0.081	14.19	0.300	0.800	
2024-144	7	M.B.MANUAL		12	11.167	4.624	41.40	0	25.000	
2024-144	24	Unicel DxH		18	7.488	0.460	6.14	5.600	9.400	
2024-144	25	SYSMEX XN		30	2.037	1.070	52.52	0	5.200	
2024-145	7	M.B.MANUAL		12	1.383	0.458	33.11	0.000	2.800	
2024-145	24	Unicel DxH		18	0.744	0.076	10.23	0.500	1.000	
2024-145	25	SYSMEX XN		30	0.583	0.069	11.78	0.400	0.800	

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 138 SED. RATE (ESR)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
153	SED. RATE (ESR)		EVALUATION CRITERIA: TARGET VALUE	3	SD OR 35 %	{GREATER}				
2024-151	4	SEDIPLAST		632	8.726	2.034	23.31	3.000	15.000	
2024-151	10	SEDI RATE		75	15.000	10.020	66.80	0	45.000	
2024-151	10	SEDI RATE		75	10.081	2.192	21.74	4.000	17.000	
2024-151	11	SEDIMAT-15		51	15.000	10.020	66.80	0	45.000	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY			SUB: 70 GENERAL			GRP: 138 SED. RATE (ESR)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-151	11	SEDIMAT-15		51	6.306	3.044	48.28	0	15.000	
2024-151	19	MINI CUBE		46	16.205	2.564	15.82	9.000	24.000	
153 SED. RATE (ESR)		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 35 % {GREATER}						
2024-152	4	SEDIPLAST		632	8.958	2.043	22.80	3.000	15.000	
2024-152	10	SEDI RATE		75	10.514	2.965	28.20	2.000	19.000	
2024-152	10	SEDI RATE		75	9.800	0.400	4.08	6.000	13.000	
2024-152	11	SEDIMAT-15		51	6.111	3.348	54.79	0	16.000	
2024-152	11	SEDIMAT-15		51	9.800	0.400	4.08	6.000	13.000	
2024-152	19	MINI CUBE		46	16.632	2.443	14.69	9.000	24.000	
2024-153	4	SEDIPLAST		632	39.741	6.776	17.05	19.000	60.000	
2024-153	10	SEDI RATE		75	44.200	7.985	18.07	20.000	68.000	
2024-153	10	SEDI RATE		75	38.945	7.339	18.84	17.000	61.000	
2024-153	11	SEDIMAT-15		51	44.200	7.985	18.07	20.000	68.000	
2024-153	11	SEDIMAT-15		51	124.429	13.124	10.55	81.000	168.000	
2024-153	19	MINI CUBE		46	50.718	14.490	28.57	7.000	94.000	
2024-154	4	SEDIPLAST		632	8.968	1.925	21.47	3.000	15.000	
2024-154	10	SEDI RATE		75	10.500	2.462	23.45	3.000	18.000	
2024-154	10	SEDI RATE		75	10.400	0.800	7.69	7.000	14.000	
2024-154	11	SEDIMAT-15		51	10.400	0.800	7.69	7.000	14.000	
2024-154	11	SEDIMAT-15		51	7.486	4.984	66.58	0	22.000	
2024-154	19	MINI CUBE		46	16.462	2.341	14.22	9.000	23.000	
2024-155	4	SEDIPLAST		632	39.526	6.740	17.05	19.000	60.000	
2024-155	10	SEDI RATE		75	45.000	7.746	17.21	22.000	68.000	
2024-155	10	SEDI RATE		75	38.685	7.121	18.41	17.000	60.000	
2024-155	11	SEDIMAT-15		51	124.543	13.670	10.98	81.000	168.000	
2024-155	11	SEDIMAT-15		51	45.000	7.746	17.21	22.000	68.000	
2024-155	19	MINI CUBE		46	58.744	16.161	27.51	10.000	107.000	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
172 DIFF. WBC FOR 5 PAR.												
CLIA TEST ID #: 765												
EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}												
2024131X	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	130	60.277	1.059	1.76	45.200	75.300
2024131X	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	131	13.519	0.654	4.84	10.100	16.900
2024131X	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	131	0.597	0.210	35.23	0	2.600
2024131X	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	131	16.048	0.300	1.87	12.000	20.100
2024131X	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	131	9.567	0.884	9.24	7.200	12.000
2024131X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	92	69.453	1.440	2.07	52.100	86.800
2024131X	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	30	66.531	1.185	1.78	49.900	83.200
2024131X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	92	23.195	1.218	5.25	17.400	29.000
2024131X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	30	21.990	1.041	4.73	16.500	27.500
2024131X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	92	2.411	0.566	23.48	0.400	4.400
2024131X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	30	2.777	0.346	12.46	0.800	4.800
2024131X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	92	4.840	0.372	7.69	2.800	6.800
2024131X	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	30	4.757	0.301	6.32	2.800	6.800
2024131X	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	92	77.568	1.524	1.97	58.200	97.000
2024131X	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	30	3.907	0.100	2.55	1.900	5.900
2024131X	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	17	71.118	0.449	0.63	53.300	88.900
2024131X	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	17	14.688	0.675	4.59	11.000	18.400
2024131X	3	ADVIA 120	3	MONOCYTE	9	ADVIA-120	17	7.347	0.212	2.88	5.300	9.300
2024131X	3	ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	17	3.212	0.219	6.83	1.200	5.200
2024131X	3	ADVIA 120	5	BASOPHIL	9	ADVIA-120	17	0.788	0.184	23.39	0	2.800
2024131X	3	ADVIA 120	6	LUC	9	ADVIA-120	17	3.129	0.304	9.73	1.100	5.100
2024131X	4	AB- CELL-D	1	NEUTROPHIL	8	CELL-DYN	50	43.741	0.859	1.96	32.800	54.700
2024131X	4	AB- CELL-D	1	NEUTROPHIL	37	ABB.CEL RU	48	43.360	1.176	2.71	32.500	54.200
2024131X	4	AB- CELL-D	2	LYMPHOCYTE	8	CELL-DYN	50	38.384	1.448	3.77	28.800	48.000
2024131X	4	AB- CELL-D	2	LYMPHOCYTE	37	ABB.CEL RU	48	39.306	1.610	4.10	29.500	49.100
2024131X	4	AB- CELL-D	3	MONOCYTE	8	CELL-DYN	50	12.898	0.892	6.92	9.700	16.100
2024131X	4	AB- CELL-D	3	MONOCYTE	37	ABB.CEL RU	48	12.896	0.881	6.83	9.700	16.100
2024131X	4	AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	50	3.524	0.309	8.77	1.500	5.500

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024131X	4	AB- CELL-D	4	EOSINOPHIL	37	ABB.CEL RU	48	3.474	0.356	10.24	1.500	5.500
2024131X	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	50	1.634	0.581	35.55	0	3.600
2024131X	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	48	0.948	0.419	44.24	0	2.900
2024131X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	61	53.343	1.051	1.97	40.000	66.700
2024131X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	61	28.048	2.078	7.41	21.000	35.100
2024131X	5	BECTON D	3	MONOCYTE	29	B.C600,800	61	8.618	1.249	14.50	6.500	10.800
2024131X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	61	9.933	0.475	4.78	7.400	12.400
2024131X	5	BECTON D	5	BASOPHIL	29	B.C600,800	61	0.000	0.000	0.00	0	2.000
2024131X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	60	49.390	1.826	3.70	37.000	61.700
2024131X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	60	38.225	2.139	5.60	28.700	47.800
2024131X	6	MR Mindray	3	MONOCYTE	32	BC-5390	60	5.170	1.308	25.29	3.200	7.200
2024131X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	59	7.198	0.711	9.88	5.200	9.200
2024131X	6	MR Mindray	5	BASOPHIL	32	BC-5390	60	29.220	0.468	1.60	21.900	36.500
2024131X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	86	76.792	1.081	1.41	57.600	96.000
2024131X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	85	14.653	1.138	7.77	11.000	18.300
2024131X	7	DXH	3	MONOCYTE	36	BC DXH 500	85	0.273	0.258	94.61	0	2.300
2024131X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	85	8.144	0.514	6.31	6.100	10.200
2024131X	7	DXH	5	BASOPHIL	36	BC DXH 500	85	0.068	0.140	206.76	0	2.100
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2024132X	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	131	55.084	1.989	3.61	41.300	68.900
2024132X	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	131	20.851	2.252	10.80	15.600	26.100
2024132X	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	131	0.739	0.286	38.70	0	2.700
2024132X	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	131	14.316	0.560	3.91	10.700	17.900
2024132X	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	131	8.912	0.776	8.71	6.700	11.100
2024132X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	92	51.971	2.706	5.21	39.000	65.000
2024132X	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	30	50.527	2.291	4.54	37.900	63.200
2024132X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	92	37.474	2.237	5.97	28.100	46.800
2024132X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	30	35.840	2.321	6.48	26.900	44.800
2024132X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	92	3.681	0.950	25.81	1.700	5.700
2024132X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	30	4.653	0.964	20.71	2.700	6.700
2024132X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	92	6.836	0.635	9.29	4.800	8.800



**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024132X	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	30	6.203	0.583	9.40	4.200	8.200
2024132X	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	92	54.292	1.258	2.32	40.700	67.900
2024132X	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	30	2.755	0.062	2.25	0.800	4.800
2024132X	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	17	44.524	1.287	2.89	33.400	55.700
2024132X	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	17	31.835	1.730	5.43	23.900	39.800
2024132X	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	17	13.988	0.740	5.29	10.500	17.500
2024132X	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	17	1.812	0.265	14.65	0	3.800
2024132X	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	17	2.800	1.031	36.83	0.800	4.800
2024132X	3	ADVIA 120	6 LUC	9	ADVIA-120	17	5.924	0.719	12.14	3.900	7.900
2024132X	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	50	72.937	0.748	1.03	54.700	91.200
2024132X	4	AB- CELL-D	1 NEUTROPHIL	37	ABB.CEL RU	48	72.769	0.814	1.12	54.600	91.000
2024132X	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	50	15.222	1.093	7.18	11.400	19.000
2024132X	4	AB- CELL-D	2 LYMPHOCYTE	37	ABB.CEL RU	48	15.523	0.879	5.66	11.600	19.400
2024132X	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	51	5.874	0.628	10.68	3.900	7.900
2024132X	4	AB- CELL-D	3 MONOCYTE	37	ABB.CEL RU	48	6.096	0.464	7.62	4.100	8.100
2024132X	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	49	4.988	0.237	4.75	3.000	7.000
2024132X	4	AB- CELL-D	4 EOSINOPHIL	37	ABB.CEL RU	48	4.998	0.234	4.68	3.000	7.000
2024132X	4	AB- CELL-D	5 BASOPHIL	8	CELL-DYN	50	0.848	0.303	35.71	0	2.800
2024132X	4	AB- CELL-D	5 BASOPHIL	37	ABB.CEL RU	48	0.619	0.154	24.85	0	2.600
2024132X	5	BECTON D	1 NEUTROPHIL	29	B.C600,800	61	68.270	0.721	1.06	51.200	85.300
2024132X	5	BECTON D	2 LYMPHOCYTE	29	B.C600,800	61	21.782	0.655	3.01	16.300	27.200
2024132X	5	BECTON D	3 MONOCYTE	29	B.C600,800	61	5.705	0.649	11.38	3.700	7.700
2024132X	5	BECTON D	4 EOSINOPHIL	29	B.C600,800	61	4.149	0.294	7.09	2.100	6.100
2024132X	5	BECTON D	5 BASOPHIL	29	B.C600,800	61	0.093	0.044	46.94	0	2.100
2024132X	6	MR Mindray	1 NEUTROPHIL	32	BC-5390	60	61.685	1.665	2.70	46.300	77.100
2024132X	6	MR Mindray	2 LYMPHOCYTE	32	BC-5390	60	19.497	1.152	5.91	14.600	24.400
2024132X	6	MR Mindray	3 MONOCYTE	32	BC-5390	59	6.122	0.773	12.62	4.100	8.100
2024132X	6	MR Mindray	4 EOSINOPHIL	32	BC-5390	61	12.532	0.553	4.42	9.400	15.700
2024132X	6	MR Mindray	5 BASOPHIL	32	BC-5390	60	31.519	0.783	2.48	23.600	39.400
2024132X	7	DXH	1 NEUTROPHIL	36	BC DXH 500	86	46.578	3.417	7.34	34.900	58.200
2024132X	7	DXH	2 LYMPHOCYTE	36	BC DXH 500	85	40.469	3.863	9.54	30.400	50.600

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024132X	7 DXH	3 MONOCYTE	36 BC DXH 500	85	0.219	0.255	116.49	0	2.200		
2024132X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	85	12.356	1.291	10.45	9.300	15.400		
2024132X	7 DXH	5 BASOPHIL	36 BC DXH 500	85	0.211	0.339	161.11	0	2.200		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2024133X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	131	60.232	1.061	1.76	45.200	75.300		
2024133X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	131	13.511	0.675	4.99	10.100	16.900		
2024133X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	130	0.595	0.194	32.65	0	2.600		
2024133X	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	131	16.031	0.303	1.89	12.000	20.000		
2024133X	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	131	9.650	0.877	9.09	7.200	12.100		
2024133X	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	92	57.080	2.033	3.56	42.800	71.400		
2024133X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	30	54.900	1.678	3.06	41.200	68.600		
2024133X	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	92	37.011	1.806	4.88	27.800	46.300		
2024133X	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	30	35.480	1.694	4.77	26.600	44.400		
2024133X	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	92	2.593	0.605	23.33	0.600	4.600		
2024133X	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	30	3.387	0.573	16.91	1.400	5.400		
2024133X	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	92	3.299	0.330	10.01	1.300	5.300		
2024133X	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	30	3.273	0.278	8.49	1.300	5.300		
2024133X	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	92	58.450	0.940	1.61	43.800	73.100		
2024133X	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	30	2.947	0.062	2.10	0.900	4.900		
2024133X	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	17	63.853	0.548	0.86	47.900	79.800		
2024133X	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	17	20.335	1.719	8.45	15.300	25.400		
2024133X	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	7.494	0.323	4.30	5.500	9.500		
2024133X	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	17	2.729	0.219	8.02	0.700	4.700		
2024133X	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	17	2.735	0.865	31.62	0.700	4.700		
2024133X	3 ADVIA 120	6 LUC	9 ADVIA-120	17	4.018	0.502	12.50	2.000	6.000		
2024133X	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	50	44.026	1.144	2.60	33.000	55.000		
2024133X	4 AB- CELL-D	1 NEUTROPHIL	37 ABB.CEL RU	48	44.513	1.432	3.22	33.400	55.600		
2024133X	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	50	37.855	1.465	3.87	28.400	47.300		
2024133X	4 AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	47	38.704	1.670	4.32	29.000	48.400		
2024133X	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	50	12.937	0.979	7.57	9.700	16.200		
2024133X	4 AB- CELL-D	3 MONOCYTE	37 ABB.CEL RU	48	12.704	0.779	6.13	9.500	15.900		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2024133X	4	AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	50	3.484	0.298	8.54	1.500	5.500
2024133X	4	AB- CELL-D	4	EOSINOPHIL	37	ABB.CEL RU	47	3.498	0.426	12.17	1.500	5.500
2024133X	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	50	1.638	0.637	38.86	0	3.600
2024133X	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	48	0.753	0.361	47.90	0	2.800
2024133X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	61	53.480	1.280	2.39	40.100	66.900
2024133X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	61	28.157	2.397	8.51	21.100	35.200
2024133X	5	BECTON D	3	MONOCYTE	29	B.C600,800	61	8.493	1.199	14.12	6.400	10.600
2024133X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	62	9.853	0.496	5.04	7.400	12.300
2024133X	5	BECTON D	5	BASOPHIL	29	B.C600,800	60	0.000	0.000	0.00	0	2.000
2024133X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	60	49.316	1.055	2.14	37.000	61.600
2024133X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	60	37.853	1.952	5.16	28.400	47.300
2024133X	6	MR Mindray	3	MONOCYTE	32	BC-5390	60	5.373	1.478	27.51	3.400	7.400
2024133X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	60	7.279	0.648	8.90	5.300	9.300
2024133X	6	MR Mindray	5	BASOPHIL	32	BC-5390	60	29.337	0.498	1.70	22.000	36.700
2024133X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	86	70.764	1.473	2.08	53.100	88.500
2024133X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	85	24.798	1.711	6.90	18.600	31.000
2024133X	7	DXH	3	MONOCYTE	36	BC DXH 500	85	0.134	0.143	106.56	0	2.100
2024133X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	85	4.083	0.499	12.21	2.100	6.100
2024133X	7	DXH	5	BASOPHIL	36	BC DXH 500	85	0.154	0.300	194.42	0	2.200
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2024134X	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	131	50.150	1.297	2.59	37.600	62.700
2024134X	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	131	27.893	1.211	4.34	20.900	34.900
2024134X	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	131	1.089	0.365	33.49	0	3.100
2024134X	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	131	12.802	0.759	5.93	9.600	16.000
2024134X	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	131	8.103	0.762	9.40	6.100	10.100
2024134X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	92	69.526	1.420	2.04	52.100	86.900
2024134X	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	30	66.493	0.970	1.46	49.900	83.100
2024134X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	92	23.057	1.008	4.37	17.300	28.800
2024134X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	30	22.045	0.893	4.05	16.500	27.600
2024134X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	92	2.380	0.500	21.00	0.400	4.400
2024134X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	30	2.710	0.351	12.94	0.700	4.700

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2024134X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	92	4.926	0.486	9.87	2.900	6.900
2024134X	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	30	4.772	0.245	5.13	2.800	6.800
2024134X	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	92	77.040	1.235	1.60	57.800	96.300
2024134X	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	30	3.876	0.090	2.31	1.900	5.900
2024134X	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	17	71.053	0.289	0.41	53.300	88.800
2024134X	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	17	14.771	0.459	3.10	11.100	18.500
2024134X	3	ADVIA 120	3	MONOCYTE	9	ADVIA-120	18	7.482	0.231	3.08	5.500	9.500
2024134X	3	ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	17	3.188	0.227	7.13	1.200	5.200
2024134X	3	ADVIA 120	5	BASOPHIL	9	ADVIA-120	17	0.759	0.191	25.19	0	2.800
2024134X	3	ADVIA 120	6	LUC	9	ADVIA-120	17	3.012	0.259	8.59	1.000	5.000
2024134X	4	AB- CELL-D	1	NEUTROPHIL	8	CELL-DYN	50	64.592	0.686	1.06	48.400	80.700
2024134X	4	AB- CELL-D	1	NEUTROPHIL	37	ABB.CEL RU	49	63.556	0.999	1.57	47.700	79.400
2024134X	4	AB- CELL-D	2	LYMPHOCYTE	8	CELL-DYN	50	24.462	1.169	4.78	18.300	30.600
2024134X	4	AB- CELL-D	2	LYMPHOCYTE	37	ABB.CEL RU	47	25.889	1.239	4.78	19.400	32.400
2024134X	4	AB- CELL-D	3	MONOCYTE	8	CELL-DYN	49	5.654	0.454	8.03	3.700	7.700
2024134X	4	AB- CELL-D	3	MONOCYTE	37	ABB.CEL RU	48	5.692	0.459	8.07	3.700	7.700
2024134X	4	AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	50	4.392	0.268	6.11	2.400	6.400
2024134X	4	AB- CELL-D	4	EOSINOPHIL	37	ABB.CEL RU	48	4.329	0.265	6.11	2.300	6.300
2024134X	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	50	1.010	0.394	38.97	0	3.000
2024134X	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	48	0.446	0.208	46.72	0	2.400
2024134X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	61	55.512	0.916	1.65	41.600	69.400
2024134X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	61	32.185	1.470	4.57	24.100	40.200
2024134X	5	BECTON D	3	MONOCYTE	29	B.C600,800	61	6.272	0.837	13.35	4.300	8.300
2024134X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	61	6.053	0.433	7.15	4.100	8.100
2024134X	5	BECTON D	5	BASOPHIL	29	B.C600,800	61	0.000	0.000	0.00	0	2.000
2024134X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	61	53.708	1.835	3.42	40.300	67.100
2024134X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	59	29.658	1.336	4.51	22.200	37.100
2024134X	6	MR Mindray	3	MONOCYTE	32	BC-5390	60	7.238	1.152	15.92	5.200	9.200
2024134X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	60	9.524	0.451	4.74	7.100	11.900
2024134X	6	MR Mindray	5	BASOPHIL	32	BC-5390	60	29.385	0.264	0.90	22.000	36.700
2024134X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	86	77.045	0.956	1.24	57.800	96.300

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024134X	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	85	14.321	1.149	8.03	10.700	17.900		
2024134X	7 DXH	3 MONOCYTE	36 BC DXH 500	85	0.195	0.204	104.52	0	2.200		
2024134X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	85	8.243	0.506	6.14	6.200	10.300		
2024134X	7 DXH	5 BASOPHIL	36 BC DXH 500	84	0.088	0.182	206.96	0	2.100		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2024135X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	131	55.124	2.108	3.82	41.300	68.900		
2024135X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	131	20.764	2.451	11.80	15.600	26.000		
2024135X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	131	0.726	0.258	35.60	0	2.700		
2024135X	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	131	14.334	0.569	3.97	10.800	17.900		
2024135X	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	131	9.078	0.766	8.44	6.800	11.300		
2024135X	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	91	56.926	1.780	3.13	42.700	71.200		
2024135X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	30	54.807	1.644	3.00	41.100	68.500		
2024135X	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	92	37.013	1.789	4.83	27.800	46.300		
2024135X	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	30	35.333	1.810	5.12	26.500	44.200		
2024135X	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	92	2.585	0.613	23.71	0.600	4.600		
2024135X	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	30	3.463	0.594	17.15	1.500	5.500		
2024135X	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	92	3.353	0.336	10.01	1.400	5.400		
2024135X	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	31	3.410	0.268	7.85	1.400	5.400		
2024135X	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	92	58.408	0.955	1.63	43.800	73.000		
2024135X	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	30	2.950	0.067	2.27	1.000	5.000		
2024135X	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	17	63.735	0.597	0.94	47.800	79.700		
2024135X	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	17	20.276	1.804	8.90	15.200	25.300		
2024135X	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	7.400	0.363	4.91	5.400	9.400		
2024135X	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	17	2.647	0.233	8.80	0.600	4.600		
2024135X	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	17	2.776	0.750	27.00	0.800	4.800		
2024135X	3 ADVIA 120	6 LUC	9 ADVIA-120	17	4.118	0.405	9.83	2.100	6.100		
2024135X	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	50	72.947	0.777	1.07	54.700	91.200		
2024135X	4 AB- CELL-D	1 NEUTROPHIL	37 ABB.CEL RU	48	72.581	0.591	0.81	54.400	90.700		
2024135X	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	50	15.133	0.775	5.12	11.400	18.900		
2024135X	4 AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	48	15.800	0.746	4.72	11.900	19.800		
2024135X	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	50	5.917	0.669	11.31	3.900	7.900		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024135X	4	AB- CELL-D	3	MONOCYTE	37	ABB.CEL RU	48	6.055	0.384	6.34	4.100	8.100
2024135X	4	AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	50	4.998	0.179	3.58	3.000	7.000
2024135X	4	AB- CELL-D	4	EOSINOPHIL	37	ABB.CEL RU	48	4.954	0.218	4.40	3.000	7.000
2024135X	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	50	0.788	0.324	41.13	0	2.800
2024135X	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	48	0.589	0.202	34.34	0	2.600
2024135X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	61	68.275	0.753	1.10	51.200	85.300
2024135X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	61	21.698	0.684	3.15	16.300	27.100
2024135X	5	BECTON D	3	MONOCYTE	29	B.C600,800	61	5.752	0.550	9.57	3.800	7.800
2024135X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	61	4.163	0.315	7.57	2.200	6.200
2024135X	5	BECTON D	5	BASOPHIL	29	B.C600,800	61	0.085	0.044	51.31	0	2.100
2024135X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	60	61.771	0.734	1.19	46.300	77.200
2024135X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	60	19.447	1.172	6.03	14.600	24.300
2024135X	6	MR Mindray	3	MONOCYTE	32	BC-5390	60	6.141	0.875	14.24	4.100	8.100
2024135X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	59	12.660	0.501	3.95	9.500	15.800
2024135X	6	MR Mindray	5	BASOPHIL	32	BC-5390	60	31.583	0.185	0.59	23.700	39.500
2024135X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	86	70.794	1.446	2.04	53.100	88.500
2024135X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	85	24.898	1.640	6.59	18.700	31.100
2024135X	7	DXH	3	MONOCYTE	36	BC DXH 500	85	0.132	0.152	115.50	0	2.100
2024135X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	85	4.026	0.467	11.61	2.000	6.000
2024135X	7	DXH	5	BASOPHIL	36	BC DXH 500	85	0.099	0.257	260.32	0	2.100

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
185 Diff 6 Parameter Ins			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2024131Y	1	6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	55	63.655	2.048	3.22	47.700	79.600
2024131Y	1	6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	191	59.492	1.966	3.30	44.600	74.400

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024131Y	1 6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	54	13.164	1.222	9.28	9.900	16.500
2024131Y	1 6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	192	14.361	1.605	11.17	10.800	18.000
2024131Y	1 6 PAR REG	3	MONOCYTE	31	SYSMEX XN	54	1.236	0.450	36.39	0	3.200
2024131Y	1 6 PAR REG	3	MONOCYTE	35	SYS XNL SR	192	0.577	0.212	36.75	0	2.600
2024131Y	1 6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	54	16.171	0.671	4.15	12.100	20.200
2024131Y	1 6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	191	15.895	0.946	5.95	11.900	19.900
2024131Y	1 6 PAR REG	5	BASOPHIL	31	SYSMEX XN	54	5.363	1.912	35.66	3.400	7.400
2024131Y	1 6 PAR REG	5	BASOPHIL	35	SYS XNL SR	192	9.436	0.932	9.88	7.100	11.800
2024131Y	1 6 PAR REG	6	IMMATURE G	31	SYSMEX XN	54	16.171	0.832	5.15	12.100	20.200
2024131Y	1 6 PAR REG	6	IMMATURE G	35	SYS XNL SR	190	16.469	1.058	6.43	12.400	20.600
2024131Y	1 6 PAR REG	7	NRBC	31	SYSMEX XN	24	0.043	0.097	223.16	0	2.000
185 Diff 6 Parameter Ins		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2024132Y	1 6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	54	57.917	1.663	2.87	43.400	72.400
2024132Y	1 6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	192	54.862	0.915	1.67	41.100	68.600
2024132Y	1 6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	54	20.011	0.833	4.17	15.000	25.000
2024132Y	1 6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	192	21.212	0.662	3.12	15.900	26.500
2024132Y	1 6 PAR REG	3	MONOCYTE	31	SYSMEX XN	54	1.815	0.581	32.00	0	3.800
2024132Y	1 6 PAR REG	3	MONOCYTE	35	SYS XNL SR	192	0.673	0.178	26.49	0	2.700
2024132Y	1 6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	54	14.877	0.453	3.05	11.200	18.600
2024132Y	1 6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	192	14.921	0.512	3.43	11.200	18.700
2024132Y	1 6 PAR REG	5	BASOPHIL	31	SYSMEX XN	54	5.357	1.512	28.22	3.400	7.400
2024132Y	1 6 PAR REG	5	BASOPHIL	35	SYS XNL SR	192	8.406	0.651	7.75	6.300	10.500
2024132Y	1 6 PAR REG	6	IMMATURE G	31	SYSMEX XN	54	14.679	0.581	3.96	11.000	18.300
2024132Y	1 6 PAR REG	6	IMMATURE G	35	SYS XNL SR	191	14.920	0.810	5.43	11.200	18.600
2024132Y	1 6 PAR REG	7	NRBC	31	SYSMEX XN	25	0.716	0.364	50.85	0	2.700
2024133Y	1 6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	54	63.858	1.834	2.87	47.900	79.800
2024133Y	1 6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	193	59.513	1.905	3.20	44.600	74.400
2024133Y	1 6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	54	13.142	1.258	9.57	9.900	16.400
2024133Y	1 6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	192	14.326	1.680	11.73	10.700	17.900

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024133Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	55	1.307	0.707	54.04	0	3.300		
2024133Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	191	0.578	0.215	37.25	0	2.600		
2024133Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	54	16.194	0.673	4.16	12.100	20.200		
2024133Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	192	16.012	0.907	5.67	12.000	20.000		
2024133Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	53	5.342	1.917	35.89	3.300	7.300		
2024133Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	191	9.424	0.763	8.10	7.100	11.800		
2024133Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	54	16.042	0.805	5.02	12.000	20.100		
2024133Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	191	16.288	0.926	5.69	12.200	20.400		
2024133Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	24	0.100	0.150	150.00	0	2.100		
185 Diff 6 Parameter Ins		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2024134Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	54	53.767	1.679	3.12	40.300	67.200		
2024134Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	191	50.750	1.172	2.31	38.100	63.400		
2024134Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	54	25.287	1.471	5.82	19.000	31.600		
2024134Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	192	27.132	0.958	3.53	20.300	33.900		
2024134Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	55	2.356	0.966	40.99	0.400	4.400		
2024134Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	192	1.017	0.212	20.88	0	3.000		
2024134Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	53	13.267	0.672	5.07	10.000	16.600		
2024134Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	192	13.253	0.771	5.82	9.900	16.600		
2024134Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	54	5.385	1.242	23.07	3.400	7.400		
2024134Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	192	7.944	0.692	8.71	5.900	9.900		
2024134Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	54	13.494	0.538	3.99	10.100	16.900		
2024134Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	192	13.837	0.726	5.25	10.400	17.300		
2024134Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	24	0.071	0.131	184.43	0	2.100		
2024135Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	54	57.830	1.624	2.81	43.400	72.300		
2024135Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	192	54.883	1.063	1.94	41.200	68.600		
2024135Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	54	20.032	0.698	3.48	15.000	25.000		
2024135Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	192	21.203	0.758	3.57	15.900	26.500		
2024135Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	54	1.806	0.596	32.99	0	3.800		
2024135Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	192	0.675	0.172	25.53	0	2.700		



**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024135Y	1	6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	54	14.791	0.412	2.78	11.100	18.500
2024135Y	1	6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	192	14.937	0.497	3.33	11.200	18.700
2024135Y	1	6 PAR REG	5	BASOPHIL	31	SYSMEX XN	54	5.463	1.702	31.16	3.500	7.500
2024135Y	1	6 PAR REG	5	BASOPHIL	35	SYS XNL SR	192	8.434	0.679	8.05	6.300	10.500
2024135Y	1	6 PAR REG	6	IMMATURE G	31	SYSMEX XN	54	14.872	0.537	3.61	11.200	18.600
2024135Y	1	6 PAR REG	6	IMMATURE G	35	SYS XNL SR	191	14.985	0.784	5.24	11.200	18.700
2024135Y	1	6 PAR REG	7	NRBC	31	SYSMEX XN	25	0.576	0.397	68.97	0	2.600

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 128 DIFF 3 PARAMETER INS

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2024131Z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	20	63.115	0.730	1.16	47.300	78.900
2024131Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	20	61.350	1.069	1.74	46.000	76.700
2024131Z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	20	12.653	0.571	4.51	9.500	15.800
2024131Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	20	10.155	0.781	7.69	7.600	12.700
2024131Z	8	3ST	3	Neutrophil	1	KX 21 - Sy	20	24.075	0.801	3.33	18.100	30.100
2024131Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	21	28.490	0.710	2.49	21.400	35.600
2024131Z	9	3D	1	Lymphocyte	2	AcT Diff 2	10	14.570	1.101	7.56	10.900	18.200
2024131Z	9	3D	2	Mix M/E/Ba	2	AcT Diff 2	10	3.230	1.045	32.35	1.200	5.200
2024131Z	9	3D	3	Neutrophil	2	AcT Diff 2	10	82.190	0.966	1.18	61.600	102.700
2024132Z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	21	13.015	0.782	6.01	9.800	16.300
2024132Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	20	14.970	1.255	8.39	11.200	18.700
2024132Z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	19	16.900	1.565	9.26	12.700	21.100
2024132Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	20	11.080	1.439	12.98	8.300	13.900
2024132Z	8	3ST	3	Neutrophil	1	KX 21 - Sy	20	70.035	1.567	2.24	52.500	87.500
2024132Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	21	73.676	2.251	3.05	55.300	92.100
2024132Z	9	3D	1	Lymphocyte	2	AcT Diff 2	10	59.920	2.094	3.49	44.900	74.900

**Participant Summary**

**MONTH 3 OF YEAR 2024**

ANALYTE			SUB: 70 GENERAL				GRP: 128 DIFF 3 PARAMETER INS						
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
2024132Z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	10	8.500	1.400	16.47	6.400	10.600		
2024132Z	9 3D	3	Neutrophil	2	AcT Diff 2	10	31.580	2.540	8.04	23.700	39.500		
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 765				EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2024133Z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	20	30.635	1.016	3.32	23.000	38.300		
2024133Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	21	30.585	1.150	3.76	22.900	38.200		
2024133Z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	20	17.530	0.953	5.44	13.100	21.900		
2024133Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	19	12.089	0.835	6.90	9.100	15.100		
2024133Z	8 3ST	3	Neutrophil	1	KX 21 - Sy	20	51.850	1.179	2.27	38.900	64.800		
2024133Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	21	57.320	1.394	2.43	43.000	71.700		
2024133Z	9 3D	1	Lymphocyte	2	AcT Diff 2	10	31.440	1.380	4.39	23.600	39.300		
2024133Z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	10	5.050	1.462	28.96	3.100	7.100		
2024133Z	9 3D	3	Neutrophil	2	AcT Diff 2	10	63.460	1.783	2.81	47.600	79.300		
2024134Z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	20	63.037	0.769	1.22	47.300	78.800		
2024134Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	20	61.360	1.360	2.22	46.000	76.700		
2024134Z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	20	13.080	0.861	6.58	9.800	16.400		
2024134Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	20	10.040	0.928	9.24	7.500	12.600		
2024134Z	8 3ST	3	Neutrophil	1	KX 21 - Sy	20	24.037	0.897	3.73	18.000	30.000		
2024134Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	21	28.240	0.992	3.51	21.200	35.300		
2024134Z	9 3D	1	Lymphocyte	2	AcT Diff 2	10	14.260	0.846	5.94	10.700	17.800		
2024134Z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	10	3.180	0.756	23.77	1.200	5.200		
2024134Z	9 3D	3	Neutrophil	2	AcT Diff 2	10	82.560	0.830	1.00	61.900	103.200		
2024135Z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	20	30.325	1.241	4.09	22.700	37.900		
2024135Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	20	30.985	1.262	4.07	23.200	38.700		
2024135Z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	20	17.825	1.114	6.25	13.400	22.300		
2024135Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	20	11.830	1.118	9.45	8.900	14.800		
2024135Z	8 3ST	3	Neutrophil	1	KX 21 - Sy	20	51.700	1.169	2.26	38.800	64.600		
2024135Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	21	56.914	2.144	3.77	42.700	71.100		
2024135Z	9 3D	1	Lymphocyte	2	AcT Diff 2	10	58.090	2.260	3.89	43.600	72.600		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 128 DIFF 3 PARAMETER INS

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024135Z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	10	8.280	2.206	26.64	6.200	10.400		
2024135Z	9 3D	3	Neutrophil	2	AcT Diff 2	10	33.580	1.800	5.36	25.200	42.000		

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 132 COMP BLOOD COUNT NEW

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE		6	%						
2024-131	1 Sysmex CBC	132	SYSMEX XS	130	2.313	0.030	1.30	2.170	2.450				
2024-131	1 Sysmex CBC	141	SYSMEX XN	50	2.298	0.031	1.35	2.160	2.440				
2024-131	1 Sysmex CBC	152	Systemex XN	200	2.282	0.030	1.31	2.150	2.420				
2024-131	2 ACT PENTRA	125	COULTER AC	94	5.188	0.086	1.66	4.880	5.500				
2024-131	2 ACT PENTRA	130	ABX PENTRA	30	5.155	0.095	1.85	4.850	5.460				
2024-131	3 ADVIA 120	116	ADVIA-120	17	5.144	0.111	2.16	4.840	5.450				
2024-131	4 AB-CELL DY	115	ABBOTT C-D	43	2.090	0.045	2.17	1.960	2.220				
2024-131	4 AB-CELL DY	153	AB-CEL-RUB	54	2.089	0.042	2.01	1.960	2.210				
2024-131	5 BECTON D	137	B.C DXH	61	2.461	0.037	1.51	2.310	2.610				
2024-131	6 MR Mindray	145	BC-5390	60	2.210	0.038	1.70	2.080	2.340				
2024-131	7 DXH500 Ser	149	BC DXH 500	83	5.164	0.099	1.92	4.850	5.470				
2024-131	8 3 ST	84	ABBOTT C-D	21	5.814	0.182	3.13	5.470	6.160				
2024-131	8 3 ST	138	SY KX-21N	15	5.793	0.084	1.46	5.450	6.140				
2024-131	9 3 D	120	COULTER	10	5.734	0.081	1.42	5.390	6.080				
2024-132	1 Sysmex CBC	132	SYSMEX XS	130	5.758	0.067	1.17	5.410	6.100				
2024-132	1 Sysmex CBC	141	SYSMEX XN	50	5.789	0.062	1.07	5.440	6.140				
2024-132	1 Sysmex CBC	152	Systemex XN	200	5.799	0.067	1.16	5.450	6.150				
2024-132	2 ACT PENTRA	125	COULTER AC	94	2.318	0.042	1.81	2.180	2.460				
2024-132	2 ACT PENTRA	130	ABX PENTRA	30	2.307	0.048	2.09	2.170	2.450				
2024-132	3 ADVIA 120	116	ADVIA-120	17	2.041	0.024	1.17	1.920	2.160				

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-132	4 AB-CELL DY	115 ABBOTT C-D		43	5.268	0.083	1.58	4.950	5.580	
2024-132	4 AB-CELL DY	153 AB-CEL-RUB		54	5.434	0.099	1.83	5.110	5.760	
2024-132	5 BECTON D	137 B.C DXH		61	5.342	0.069	1.29	5.020	5.660	
2024-132	6 MR Mindray	145 BC-5390		60	5.453	0.106	1.94	5.130	5.780	
2024-132	7 DXH500 Ser	149 BC DXH 500		83	2.383	0.046	1.93	2.240	2.530	
2024-132	8 3 ST	84 ABBOTT C-D		21	2.407	0.066	2.74	2.260	2.550	
2024-132	8 3 ST	138 SY KX-21N		15	2.387	0.033	1.40	2.240	2.530	
2024-132	9 3 D	120 COULTER		10	2.368	0.041	1.73	2.230	2.510	
549 RED CELL COUNT (RBC)		CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 6 %						
2024-133	1 Sysmex CBC	132 SYSMEX XS		130	2.311	0.030	1.28	2.170	2.450	
2024-133	1 Sysmex CBC	141 SYSMEX XN		50	2.294	0.028	1.22	2.160	2.430	
2024-133	1 Sysmex CBC	152 Sysmex XN		200	2.284	0.028	1.22	2.150	2.420	
2024-133	2 ACT PENTRA	125 COULTER AC		94	4.525	0.071	1.57	4.250	4.800	
2024-133	2 ACT PENTRA	130 ABX PENTRA		30	4.497	0.076	1.70	4.230	4.770	
2024-133	3 ADVIA 120	116 ADVIA-120		17	4.158	0.103	2.48	3.910	4.410	
2024-133	4 AB-CELL DY	115 ABBOTT C-D		43	2.092	0.038	1.82	1.970	2.220	
2024-133	4 AB-CELL DY	153 AB-CEL-RUB		54	2.093	0.044	2.10	1.970	2.220	
2024-133	5 BECTON D	137 B.C DXH		61	2.457	0.035	1.44	2.310	2.600	
2024-133	6 MR Mindray	145 BC-5390		60	2.223	0.036	1.64	2.090	2.360	
2024-133	7 DXH500 Ser	149 BC DXH 500		83	4.660	0.071	1.53	4.380	4.940	
2024-133	8 3 ST	84 ABBOTT C-D		21	4.144	0.112	2.71	3.900	4.390	
2024-133	8 3 ST	138 SY KX-21N		15	4.099	0.064	1.56	3.850	4.350	
2024-133	9 3 D	120 COULTER		10	4.589	0.060	1.31	4.310	4.860	
2024-134	1 Sysmex CBC	132 SYSMEX XS		130	4.531	0.050	1.10	4.260	4.800	
2024-134	1 Sysmex CBC	141 SYSMEX XN		50	4.535	0.046	1.02	4.260	4.810	
2024-134	1 Sysmex CBC	152 Sysmex XN		200	4.530	0.051	1.12	4.260	4.800	
2024-134	2 ACT PENTRA	125 COULTER AC		94	5.173	0.081	1.56	4.860	5.480	
2024-134	2 ACT PENTRA	130 ABX PENTRA		30	5.142	0.088	1.71	4.830	5.450	
2024-134	3 ADVIA 120	116 ADVIA-120		17	5.156	0.089	1.72	4.850	5.470	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-134	4	AB-CELL DY	115 ABBOTT C-D	43	4.762	0.081	1.70	4.480	5.050		
2024-134	4	AB-CELL DY	153 AB-CEL-RUB	54	4.865	0.100	2.05	4.570	5.160		
2024-134	5	BECTON D	137 B.C DXH	61	4.008	0.054	1.34	3.770	4.250		
2024-134	6	MR Mindray	145 BC-5390	60	4.497	0.074	1.64	4.230	4.770		
2024-134	7	DXH500 Ser	149 BC DXH 500	83	5.137	0.073	1.43	4.830	5.450		
2024-134	8	3 ST	84 ABBOTT C-D	21	5.805	0.195	3.37	5.460	6.150		
2024-134	8	3 ST	138 SY KX-21N	15	5.790	0.074	1.28	5.440	6.140		
2024-134	9	3 D	120 COULTER	10	5.800	0.123	2.11	5.450	6.150		
549	RED CELL COUNT (RBC)		CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 6 %							
2024-135	1	Sysmex CBC	132 SYSMEX XS	130	5.766	0.076	1.31	5.420	6.110		
2024-135	1	Sysmex CBC	141 SYSMEX XN	50	5.782	0.060	1.03	5.430	6.130		
2024-135	1	Sysmex CBC	152 Sysmex XN	200	5.806	0.062	1.06	5.460	6.150		
2024-135	2	ACT PENTRA	125 COULTER AC	94	4.528	0.067	1.48	4.260	4.800		
2024-135	2	ACT PENTRA	130 ABX PENTRA	30	4.488	0.067	1.50	4.220	4.760		
2024-135	3	ADVIA 120	116 ADVIA-120	17	4.159	0.101	2.43	3.910	4.410		
2024-135	4	AB-CELL DY	115 ABBOTT C-D	43	5.247	0.065	1.25	4.930	5.560		
2024-135	4	AB-CELL DY	153 AB-CEL-RUB	54	5.374	0.134	2.49	5.050	5.700		
2024-135	5	BECTON D	137 B.C DXH	61	5.337	0.059	1.10	5.020	5.660		
2024-135	6	MR Mindray	145 BC-5390	60	5.445	0.096	1.76	5.120	5.770		
2024-135	7	DXH500 Ser	149 BC DXH 500	83	4.659	0.085	1.83	4.380	4.940		
2024-135	8	3 ST	84 ABBOTT C-D	21	4.153	0.114	2.73	3.900	4.400		
2024-135	8	3 ST	138 SY KX-21N	15	4.109	0.054	1.33	3.860	4.360		
2024-135	9	3 D	120 COULTER	10	2.367	0.065	2.76	2.230	2.510		
550	HEMATOCRIT (HCT)		CLIA TEST ID #: 785								
2024-131	1	Sysmex CBC	132 SYSMEX XS	131	17.960	0.386	2.15	16.900	19.000		
2024-131	1	Sysmex CBC	141 SYSMEX XN	50	17.200	0.354	2.06	16.200	18.200		
2024-131	1	Sysmex CBC	152 Sysmex XN	198	17.403	0.332	1.91	16.400	18.400		
2024-131	2	ACT PENTRA	125 COULTER AC	94	47.423	0.979	2.06	44.600	50.300		
2024-131	2	ACT PENTRA	130 ABX PENTRA	30	47.203	0.890	1.89	44.400	50.000		
2024-131	3	ADVIA 120	116 ADVIA-120	17	45.347	1.170	2.58	42.600	48.100		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-131	4	AB-CELL DY	115 ABBOTT C-D	45	15.780	0.429	2.72	14.800	16.700	
2024-131	4	AB-CELL DY	153 AB-CEL-RUB	53	15.865	0.333	2.10	14.900	16.800	
2024-131	5	BECTON D	137 B.C DXH	61	20.234	0.297	1.47	19.000	21.400	
2024-131	6	MR Mindray	145 BC-5390	60	16.917	0.459	2.71	15.900	17.900	
2024-131	7	DXH500 Ser	149 BC DXH 500	83	49.632	0.871	1.76	46.700	52.600	
2024-131	8	3 ST	84 ABBOTT C-D	21	52.862	1.321	2.50	49.700	56.000	
2024-131	8	3 ST	138 SY KX-21N	15	50.320	0.813	1.61	47.300	53.300	
2024-131	9	3 D	120 COULTER	10	53.720	1.350	2.51	50.500	56.900	
550 HEMATOCRIT (HCT)		CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 6 %						
2024-132	1	Sysmex CBC	132 SYSMEX XS	131	53.478	0.984	1.84	50.300	56.700	
2024-132	1	Sysmex CBC	141 SYSMEX XN	50	51.872	0.867	1.67	48.800	55.000	
2024-132	1	Sysmex CBC	152 Sysmex XN	198	52.537	0.850	1.62	49.400	55.700	
2024-132	2	ACT PENTRA	125 COULTER AC	94	17.691	0.380	2.15	16.600	18.800	
2024-132	2	ACT PENTRA	130 ABX PENTRA	30	17.497	0.347	1.98	16.400	18.500	
2024-132	3	ADVIA 120	116 ADVIA-120	17	14.876	0.339	2.28	14.000	15.800	
2024-132	4	AB-CELL DY	115 ABBOTT C-D	45	45.270	1.108	2.45	42.600	48.000	
2024-132	4	AB-CELL DY	153 AB-CEL-RUB	53	47.260	0.868	1.84	44.400	50.100	
2024-132	5	BECTON D	137 B.C DXH	61	56.326	0.824	1.46	52.900	59.700	
2024-132	6	MR Mindray	145 BC-5390	60	48.702	1.168	2.40	45.800	51.600	
2024-132	7	DXH500 Ser	149 BC DXH 500	83	18.665	0.383	2.05	17.500	19.800	
2024-132	8	3 ST	84 ABBOTT C-D	21	17.905	0.543	3.03	16.800	19.000	
2024-132	8	3 ST	138 SY KX-21N	15	17.107	0.389	2.27	16.100	18.100	
2024-132	9	3 D	120 COULTER	10	17.770	0.434	2.44	16.700	18.800	
2024-133	1	Sysmex CBC	132 SYSMEX XS	131	17.928	0.392	2.19	16.900	19.000	
2024-133	1	Sysmex CBC	141 SYSMEX XN	50	17.152	0.357	2.08	16.100	18.200	
2024-133	1	Sysmex CBC	152 Sysmex XN	198	17.396	0.299	1.72	16.400	18.400	
2024-133	2	ACT PENTRA	125 COULTER AC	94	38.021	0.705	1.85	35.700	40.300	
2024-133	2	ACT PENTRA	130 ABX PENTRA	30	37.907	0.693	1.83	35.600	40.200	
2024-133	3	ADVIA 120	116 ADVIA-120	17	34.482	1.080	3.13	32.400	36.600	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-133	4	AB-CELL DY	115 ABBOTT C-D	45	15.775	0.433	2.75	14.800	16.700	
2024-133	4	AB-CELL DY	153 AB-CEL-RUB	53	15.902	0.390	2.45	14.900	16.900	
2024-133	5	BECTON D	137 B.C DXH	61	20.190	0.276	1.37	19.000	21.400	
2024-133	6	MR Mindray	145 BC-5390	60	16.925	0.383	2.26	15.900	17.900	
2024-133	7	DXH500 Ser	149 BC DXH 500	83	42.148	0.698	1.66	39.600	44.700	
2024-133	8	3 ST	84 ABBOTT C-D	21	33.905	0.880	2.60	31.900	35.900	
2024-133	8	3 ST	138 SY KX-21N	15	31.887	0.677	2.12	30.000	33.800	
2024-133	9	3 D	120 COULTER	10	39.440	1.042	2.64	37.100	41.800	
550 HEMATOCRIT (HCT)		CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 6 %						
2024-134	1	Sysmex CBC	132 SYSMEX XS	131	39.726	0.776	1.95	37.300	42.100	
2024-134	1	Sysmex CBC	141 SYSMEX XN	50	38.572	0.635	1.65	36.300	40.900	
2024-134	1	Sysmex CBC	152 Sysmex XN	198	39.039	0.658	1.69	36.700	41.400	
2024-134	2	ACT PENTRA	125 COULTER AC	94	47.325	1.027	2.17	44.500	50.200	
2024-134	2	ACT PENTRA	130 ABX PENTRA	30	47.113	0.810	1.72	44.300	49.900	
2024-134	3	ADVIA 120	116 ADVIA-120	17	45.382	1.177	2.59	42.700	48.100	
2024-134	4	AB-CELL DY	115 ABBOTT C-D	45	38.464	0.890	2.31	36.200	40.800	
2024-134	4	AB-CELL DY	153 AB-CEL-RUB	53	39.685	0.844	2.13	37.300	42.100	
2024-134	5	BECTON D	137 B.C DXH	61	38.551	0.540	1.40	36.200	40.900	
2024-134	6	MR Mindray	145 BC-5390	60	37.795	0.873	2.31	35.500	40.100	
2024-134	7	DXH500 Ser	149 BC DXH 500	83	49.443	0.715	1.45	46.500	52.400	
2024-134	8	3 ST	84 ABBOTT C-D	21	52.757	1.365	2.59	49.600	55.900	
2024-134	8	3 ST	138 SY KX-21N	15	50.353	0.851	1.69	47.300	53.400	
2024-134	9	3 D	120 COULTER	10	54.220	1.745	3.22	51.000	57.500	
2024-135	1	Sysmex CBC	132 SYSMEX XS	131	53.443	1.076	2.01	50.200	56.600	
2024-135	1	Sysmex CBC	141 SYSMEX XN	50	51.848	0.778	1.50	48.700	55.000	
2024-135	1	Sysmex CBC	152 Sysmex XN	198	52.566	0.908	1.73	49.400	55.700	
2024-135	2	ACT PENTRA	125 COULTER AC	94	38.043	0.691	1.82	35.800	40.300	
2024-135	2	ACT PENTRA	130 ABX PENTRA	30	37.823	0.646	1.71	35.600	40.100	
2024-135	3	ADVIA 120	116 ADVIA-120	17	34.471	0.965	2.80	32.400	36.500	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-135	4	AB-CELL DY	115 ABBOTT C-D	45	45.123	1.192	2.64	42.400	47.800	
2024-135	4	AB-CELL DY	153 AB-CEL-RUB	53	46.738	1.142	2.44	43.900	49.500	
2024-135	5	BECTON D	137 B.C DXH	61	56.374	0.747	1.32	53.000	59.800	
2024-135	6	MR Mindray	145 BC-5390	60	48.632	1.150	2.36	45.700	51.600	
2024-135	7	DXH500 Ser	149 BC DXH 500	83	42.149	0.765	1.82	39.600	44.700	
2024-135	8	3 ST	84 ABBOTT C-D	21	33.995	1.018	2.99	32.000	36.000	
2024-135	8	3 ST	138 SY KX-21N	15	31.920	0.610	1.91	30.000	33.800	
2024-135	9	3 D	120 COULTER	10	17.740	0.693	3.91	16.700	18.800	
551 HEMOGLOBIN (HGB)			CLIA TEST ID #: 795					EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}		
2024-131	1	Sysmex CBC	132 SYSMEX XS	131	5.799	0.086	1.49	5.400	6.200	
2024-131	1	Sysmex CBC	141 SYSMEX XN	50	5.896	0.111	1.89	5.500	6.300	
2024-131	1	Sysmex CBC	152 Sysmex XN	197	5.885	0.070	1.19	5.500	6.300	
2024-131	2	ACT PENTRA	125 COULTER AC	94	16.654	0.296	1.78	15.500	17.800	
2024-131	2	ACT PENTRA	130 ABX PENTRA	30	16.650	0.236	1.42	15.500	17.800	
2024-131	3	ADVIA 120	116 ADVIA-120	17	16.741	0.197	1.18	15.600	17.900	
2024-131	4	AB-CELL DY	115 ABBOTT C-D	45	5.869	0.101	1.72	5.500	6.300	
2024-131	4	AB-CELL DY	153 AB-CEL-RUB	53	5.717	0.101	1.77	5.300	6.100	
2024-131	5	BECTON D	137 B.C DXH	61	6.385	0.088	1.38	5.900	6.800	
2024-131	6	MR Mindray	145 BC-5390	61	5.737	0.112	1.96	5.300	6.100	
2024-131	7	DXH500 Ser	149 BC DXH 500	83	17.429	0.254	1.46	16.200	18.600	
2024-131	8	3 ST	84 ABBOTT C-D	21	18.205	0.446	2.45	16.900	19.500	
2024-131	8	3 ST	138 SY KX-21N	15	18.393	0.605	3.29	17.100	19.700	
2024-131	9	3 D	120 COULTER	10	18.610	0.291	1.57	17.300	19.900	
2024-132	1	Sysmex CBC	132 SYSMEX XS	131	17.801	0.214	1.20	16.600	19.000	
2024-132	1	Sysmex CBC	141 SYSMEX XN	50	17.820	0.197	1.10	16.600	19.100	
2024-132	1	Sysmex CBC	152 Sysmex XN	197	17.796	0.151	0.85	16.600	19.000	
2024-132	2	ACT PENTRA	125 COULTER AC	94	6.111	0.123	2.01	5.700	6.500	
2024-132	2	ACT PENTRA	130 ABX PENTRA	30	5.967	0.101	1.69	5.500	6.400	
2024-132	3	ADVIA 120	116 ADVIA-120	17	5.594	0.087	1.56	5.200	6.000	



**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-132	4	AB-CELL DY	115 ABBOTT C-D	45	17.007	0.321	1.89	15.800	18.200	
2024-132	4	AB-CELL DY	153 AB-CEL-RUB	53	17.177	0.278	1.62	16.000	18.400	
2024-132	5	BECTON D	137 B.C DXH	61	16.930	0.159	0.94	15.700	18.100	
2024-132	6	MR Mindray	145 BC-5390	61	17.222	0.353	2.05	16.000	18.400	
2024-132	7	DXH500 Ser	149 BC DXH 500	83	6.339	0.090	1.42	5.900	6.800	
2024-132	8	3 ST	84 ABBOTT C-D	21	6.467	0.181	2.80	6.000	6.900	
2024-132	8	3 ST	138 SY KX-21N	15	6.367	0.255	4.00	5.900	6.800	
2024-132	9	3 D	120 COULTER	10	6.060	0.156	2.58	5.600	6.500	
551 HEMOGLOBIN (HGB)		CLIA TEST ID #: 795		EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}						
2024-133	1	Sysmex CBC	132 SYSMEX XS	131	5.829	0.175	3.00	5.400	6.200	
2024-133	1	Sysmex CBC	141 SYSMEX XN	50	5.918	0.105	1.78	5.500	6.300	
2024-133	1	Sysmex CBC	152 Sysmex XN	197	5.902	0.068	1.15	5.500	6.300	
2024-133	2	ACT PENTRA	125 COULTER AC	94	13.344	0.213	1.60	12.400	14.300	
2024-133	2	ACT PENTRA	130 ABX PENTRA	30	13.297	0.197	1.49	12.400	14.200	
2024-133	3	ADVIA 120	116 ADVIA-120	17	12.741	0.175	1.37	11.800	13.600	
2024-133	4	AB-CELL DY	115 ABBOTT C-D	45	5.858	0.114	1.95	5.400	6.300	
2024-133	4	AB-CELL DY	153 AB-CEL-RUB	53	5.675	0.110	1.93	5.300	6.100	
2024-133	5	BECTON D	137 B.C DXH	61	6.395	0.082	1.28	5.900	6.800	
2024-133	6	MR Mindray	145 BC-5390	61	5.750	0.109	1.89	5.300	6.200	
2024-133	7	DXH500 Ser	149 BC DXH 500	83	14.733	0.178	1.21	13.700	15.800	
2024-133	8	3 ST	84 ABBOTT C-D	21	11.924	0.256	2.15	11.100	12.800	
2024-133	8	3 ST	138 SY KX-21N	15	11.886	0.203	1.71	11.100	12.700	
2024-133	9	3 D	120 COULTER	10	13.760	0.341	2.48	12.800	14.700	
2024-134	1	Sysmex CBC	132 SYSMEX XS	131	13.266	0.152	1.15	12.300	14.200	
2024-134	1	Sysmex CBC	141 SYSMEX XN	50	13.376	0.158	1.18	12.400	14.300	
2024-134	1	Sysmex CBC	152 Sysmex XN	197	13.349	0.115	0.86	12.400	14.300	
2024-134	2	ACT PENTRA	125 COULTER AC	94	16.642	0.263	1.58	15.500	17.800	
2024-134	2	ACT PENTRA	130 ABX PENTRA	30	16.673	0.224	1.34	15.500	17.800	
2024-134	3	ADVIA 120	116 ADVIA-120	17	16.741	0.191	1.14	15.600	17.900	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-134	4 AB-CELL DY	115 ABBOTT C-D		45	13.798	0.253	1.83	12.800	14.800		
2024-134	4 AB-CELL DY	153 AB-CEL-RUB		53	13.857	0.232	1.67	12.900	14.800		
2024-134	5 BECTON D	137 B.C DXH		61	12.066	0.150	1.25	11.200	12.900		
2024-134	6 MR Mindray	145 BC-5390		61	13.333	0.213	1.59	12.400	14.300		
2024-134	7 DXH500 Ser	149 BC DXH 500		83	17.287	0.219	1.27	16.100	18.500		
2024-134	8 3 ST	84 ABBOTT C-D		21	18.229	0.420	2.30	17.000	19.500		
2024-134	8 3 ST	138 SY KX-21N		15	18.367	0.643	3.50	17.100	19.700		
2024-134	9 3 D	120 COULTER		10	18.680	0.451	2.42	17.400	20.000		
551	HEMOGLOBIN (HGB)	CLIA TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}								
2024-135	1 Sysmex CBC	132 SYSMEX XS		131	17.824	0.209	1.17	16.600	19.100		
2024-135	1 Sysmex CBC	141 SYSMEX XN		50	17.840	0.224	1.25	16.600	19.100		
2024-135	1 Sysmex CBC	152 Sysmex XN		197	17.810	0.145	0.82	16.600	19.100		
2024-135	2 ACT PENTRA	125 COULTER AC		94	13.357	0.222	1.66	12.400	14.300		
2024-135	2 ACT PENTRA	130 ABX PENTRA		30	13.290	0.162	1.22	12.400	14.200		
2024-135	3 ADVIA 120	116 ADVIA-120		17	12.747	0.228	1.79	11.900	13.600		
2024-135	4 AB-CELL DY	115 ABBOTT C-D		45	17.000	0.296	1.74	15.800	18.200		
2024-135	4 AB-CELL DY	153 AB-CEL-RUB		53	17.102	0.239	1.40	15.900	18.300		
2024-135	5 BECTON D	137 B.C DXH		61	16.962	0.182	1.07	15.800	18.100		
2024-135	6 MR Mindray	145 BC-5390		61	17.188	0.302	1.76	16.000	18.400		
2024-135	7 DXH500 Ser	149 BC DXH 500		83	14.652	0.202	1.38	13.600	15.700		
2024-135	8 3 ST	84 ABBOTT C-D		21	11.976	0.326	2.73	11.100	12.800		
2024-135	8 3 ST	138 SY KX-21N		15	11.907	0.153	1.29	11.100	12.700		
2024-135	9 3 D	120 COULTER		10	6.090	0.197	3.24	5.700	6.500		
552	WHITE CELL COUNT (WBC)	CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %								
2024-131	1 Sysmex CBC	132 SYSMEX XS		131	3.949	0.156	3.94	3.400	4.500		
2024-131	1 Sysmex CBC	141 SYSMEX XN		50	3.892	0.103	2.64	3.300	4.500		
2024-131	1 Sysmex CBC	152 Sysmex XN		197	3.561	0.272	7.65	3.000	4.100		
2024-131	2 ACT PENTRA	125 COULTER AC		95	19.015	0.727	3.82	16.200	21.900		
2024-131	2 ACT PENTRA	130 ABX PENTRA		30	18.750	0.560	2.98	15.900	21.600		
2024-131	3 ADVIA 120	116 ADVIA-120		17	18.276	0.723	3.96	15.500	21.000		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-131	4	AB-CELL DY	115 ABBOTT C-D	45	3.168	0.110	3.48	2.700	3.600	
2024-131	4	AB-CELL DY	153 AB-CEL-RUB	53	3.123	0.125	4.00	2.700	3.600	
2024-131	5	BECTON D	137 B.C DXH	61	4.525	0.158	3.49	3.800	5.200	
2024-131	6	MR Mindray	145 BC-5390	61	3.317	0.211	6.35	2.800	3.800	
2024-131	7	DXH500 Ser	149 BC DXH 500	82	17.891	0.439	2.46	15.200	20.600	
2024-131	8	3 ST	84 ABBOTT C-D	21	20.886	0.990	4.74	17.800	24.000	
2024-131	8	3 ST	138 SY KX-21N	15	21.073	0.659	3.13	17.900	24.200	
2024-131	9	3 D	120 COULTER	10	21.500	0.502	2.33	18.300	24.700	
552 WHITE CELL COUNT(WBC)		CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %							
2024-132	1	Sysmex CBC	132 SYSMEX XS	131	20.813	0.658	3.16	17.700	23.900	
2024-132	1	Sysmex CBC	141 SYSMEX XN	50	21.348	0.532	2.49	18.100	24.600	
2024-132	1	Sysmex CBC	152 Sysmex XN	197	20.907	0.402	1.92	17.800	24.000	
2024-132	2	ACT PENTRA	125 COULTER AC	95	3.098	0.132	4.28	2.600	3.600	
2024-132	2	ACT PENTRA	130 ABX PENTRA	30	3.047	0.136	4.46	2.600	3.500	
2024-132	3	ADVIA 120	116 ADVIA-120	17	3.388	0.108	3.18	2.900	3.900	
2024-132	4	AB-CELL DY	115 ABBOTT C-D	45	20.582	0.459	2.23	17.500	23.700	
2024-132	4	AB-CELL DY	153 AB-CEL-RUB	53	20.191	0.539	2.67	17.200	23.200	
2024-132	5	BECTON D	137 B.C DXH	61	21.748	0.418	1.92	18.500	25.000	
2024-132	6	MR Mindray	145 BC-5390	61	18.680	0.863	4.62	15.900	21.500	
2024-132	7	DXH500 Ser	149 BC DXH 500	82	2.129	0.097	4.55	1.800	2.400	
2024-132	8	3 ST	84 ABBOTT C-D	21	2.905	0.168	5.77	2.500	3.300	
2024-132	8	3 ST	138 SY KX-21N	15	2.814	0.099	3.52	2.400	3.200	
2024-132	9	3 D	120 COULTER	10	2.280	0.117	5.11	1.900	2.600	
2024-133	1	Sysmex CBC	132 SYSMEX XS	131	3.956	0.140	3.55	3.400	4.500	
2024-133	1	Sysmex CBC	141 SYSMEX XN	50	3.908	0.172	4.41	3.300	4.500	
2024-133	1	Sysmex CBC	152 Sysmex XN	197	3.585	0.236	6.58	3.000	4.100	
2024-133	2	ACT PENTRA	125 COULTER AC	95	8.625	0.291	3.37	7.300	9.900	
2024-133	2	ACT PENTRA	130 ABX PENTRA	30	8.557	0.263	3.07	7.300	9.800	
2024-133	3	ADVIA 120	116 ADVIA-120	17	7.865	0.423	5.38	6.700	9.000	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-133	4 AB-CELL DY	115 ABBOTT C-D		45	3.211	0.111	3.46	2.700	3.700		
2024-133	4 AB-CELL DY	153 AB-CEL-RUB		53	3.246	0.135	4.16	2.800	3.700		
2024-133	5 BECTON D	137 B.C DXH		61	4.526	0.166	3.66	3.800	5.200		
2024-133	6 MR Mindray	145 BC-5390		61	3.315	0.119	3.60	2.800	3.800		
2024-133	7 DXH500 Ser	149 BC DXH 500		82	7.621	0.229	3.00	6.500	8.800		
2024-133	8 3 ST	84 ABBOTT C-D		21	7.952	0.366	4.60	6.800	9.100		
2024-133	8 3 ST	138 SY KX-21N		15	8.167	0.218	2.67	6.900	9.400		
2024-133	9 3 D	120 COULTER		10	8.250	0.112	1.36	7.000	9.500		
552 WHITE CELL COUNT(WBC)		CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %								
2024-134	1 Sysmex CBC	132 SYSMEX XS		131	7.410	0.338	4.56	6.300	8.500		
2024-134	1 Sysmex CBC	141 SYSMEX XN		50	7.857	0.193	2.45	6.700	9.000		
2024-134	1 Sysmex CBC	152 Sysmex XN		197	7.356	0.216	2.93	6.300	8.500		
2024-134	2 ACT PENTRA	125 COULTER AC		95	18.887	0.637	3.37	16.100	21.700		
2024-134	2 ACT PENTRA	130 ABX PENTRA		30	18.770	0.539	2.87	16.000	21.600		
2024-134	3 ADVIA 120	116 ADVIA-120		17	18.244	0.540	2.96	15.500	21.000		
2024-134	4 AB-CELL DY	115 ABBOTT C-D		45	7.789	0.185	2.38	6.600	9.000		
2024-134	4 AB-CELL DY	153 AB-CEL-RUB		53	7.672	0.207	2.70	6.500	8.800		
2024-134	5 BECTON D	137 B.C DXH		61	9.618	0.193	2.01	8.200	11.100		
2024-134	6 MR Mindray	145 BC-5390		61	8.082	0.200	2.47	6.900	9.300		
2024-134	7 DXH500 Ser	149 BC DXH 500		82	17.746	0.390	2.20	15.100	20.400		
2024-134	8 3 ST	84 ABBOTT C-D		21	20.743	0.983	4.74	17.600	23.900		
2024-134	8 3 ST	138 SY KX-21N		15	20.979	0.694	3.31	17.800	24.100		
2024-134	9 3 D	120 COULTER		10	21.840	0.356	1.63	18.600	25.100		
2024-135	1 Sysmex CBC	132 SYSMEX XS		131	20.840	0.656	3.15	17.700	24.000		
2024-135	1 Sysmex CBC	141 SYSMEX XN		50	21.376	0.456	2.13	18.200	24.600		
2024-135	1 Sysmex CBC	152 Sysmex XN		197	20.934	0.376	1.79	17.800	24.100		
2024-135	2 ACT PENTRA	125 COULTER AC		95	8.693	0.276	3.17	7.400	10.000		
2024-135	2 ACT PENTRA	130 ABX PENTRA		30	8.597	0.229	2.66	7.300	9.900		
2024-135	3 ADVIA 120	116 ADVIA-120		17	7.965	0.379	4.76	6.800	9.200		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-135	4	AB-CELL DY	115 ABBOTT C-D	45	20.636	0.539	2.61	17.500	23.700
2024-135	4	AB-CELL DY	153 AB-CEL-RUB	53	20.158	0.498	2.47	17.100	23.200
2024-135	5	BECTON D	137 B.C DXH	61	21.716	0.424	1.95	18.500	25.000
2024-135	6	MR Mindray	145 BC-5390	61	18.632	0.632	3.39	15.800	21.400
2024-135	7	DXH500 Ser	149 BC DXH 500	82	7.623	0.204	2.68	6.500	8.800
2024-135	8	3 ST	84 ABBOTT C-D	21	8.110	0.262	3.24	6.900	9.300
2024-135	8	3 ST	138 SY KX-21N	15	8.180	0.288	3.52	7.000	9.400
2024-135	9	3 D	120 COULTER	10	2.310	0.094	4.08	2.000	2.700

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 134 PLATELET COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
553 PLATELET COUNT				CLIA TEST ID #: 815      EVALUATION CRITERIA: TARGET VALUE 25 %					
2024-131	1	SYSMEX CBC	79 SYSMEX XS	130	56.008	3.912	6.98	42.000	70.000
2024-131	1	SYSMEX CBC	87 SYSMEX XN	51	49.490	3.051	6.16	37.000	62.000
2024-131	1	SYSMEX CBC	98 SYSMEX 350	198	50.858	2.977	5.85	38.000	64.000
2024-131	2	ACT5 PENTR	73 COULTER AC	91	441.800	16.495	3.73	331.000	552.000
2024-131	2	ACT5 PENTR	78 ABX PENTRA	30	432.900	11.476	2.65	325.000	541.000
2024-131	3	ADVIA 120	64 ADVIA-120	17	448.588	31.554	7.03	336.000	561.000
2024-131	4	AB- CELL-D	63 ABBOTT C-D	44	79.512	5.630	7.08	60.000	99.000
2024-131	4	AB- CELL-D	100 ABB.RUBY	53	76.865	5.512	7.17	58.000	96.000
2024-131	4	AB- CELL-D	100 ABB.RUBY	53	80.778	6.033	7.47	61.000	101.000
2024-131	5	BECTON D	83 B.C600,800	61	87.377	2.625	3.00	66.000	109.000
2024-131	6	MR Mindray	91 BC-5390	60	53.102	6.490	12.22	40.000	66.000
2024-131	8	3 ST	31 ABBOTT C-D	21	365.810	64.978	17.76	274.000	457.000
2024-131	8	3 ST	84 KX21,300	16	397.438	19.481	4.90	298.000	497.000
2024-131	9	3 D	68 COULTERACT	10	599.700	29.162	4.86	450.000	750.000
2024-131	10	DxH	94 BC DXH 500	83	488.753	23.542	4.82	367.000	611.000

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
553	PLATELET COUNT	CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-132	1	SYSMEX CBC	79	SYSMEX XS	130	375.283	24.255	6.46	281.000	469.000	
2024-132	1	SYSMEX CBC	87	SYSMEX XN	51	407.400	12.366	3.04	306.000	509.000	
2024-132	1	SYSMEX CBC	98	SYSMEX 350	198	403.449	15.926	3.95	303.000	504.000	
2024-132	2	ACT5 PENTR	73	COULTER AC	91	69.233	5.232	7.56	52.000	87.000	
2024-132	2	ACT5 PENTR	78	ABX PENTRA	30	68.533	4.780	6.97	51.000	86.000	
2024-132	3	ADVIA 120	64	ADVIA-120	17	59.882	6.720	11.22	45.000	75.000	
2024-132	4	AB- CELL-D	63	ABBOTT C-D	44	477.318	28.653	6.00	358.000	597.000	
2024-132	4	AB- CELL-D	100	ABB.RUBY	53	457.000	14.959	3.27	343.000	571.000	
2024-132	4	AB- CELL-D	100	ABB.RUBY	53	482.096	21.235	4.40	362.000	603.000	
2024-132	5	BECTON D	83	B.C600,800	61	475.557	14.829	3.12	357.000	594.000	
2024-132	6	MR Mindray	91	BC-5390	60	535.746	29.485	5.50	402.000	670.000	
2024-132	8	3 ST	31	ABBOTT C-D	21	65.762	8.234	12.52	49.000	82.000	
2024-132	8	3 ST	84	KX21,300	16	65.563	4.886	7.45	49.000	82.000	
2024-132	9	3 D	68	COULTERAcT	10	78.400	6.344	8.09	59.000	98.000	
2024-132	10	DxH	94	BC DXH 500	83	78.561	5.210	6.63	59.000	98.000	
2024-133	1	SYSMEX CBC	79	SYSMEX XS	130	55.961	4.223	7.55	42.000	70.000	
2024-133	1	SYSMEX CBC	87	SYSMEX XN	51	50.275	3.150	6.27	38.000	63.000	
2024-133	1	SYSMEX CBC	98	SYSMEX 350	198	51.071	2.904	5.69	38.000	64.000	
2024-133	2	ACT5 PENTR	73	COULTER AC	91	227.578	9.523	4.18	171.000	284.000	
2024-133	2	ACT5 PENTR	78	ABX PENTRA	30	224.933	8.152	3.62	169.000	281.000	
2024-133	3	ADVIA 120	64	ADVIA-120	17	227.471	17.392	7.65	171.000	284.000	
2024-133	4	AB- CELL-D	63	ABBOTT C-D	44	78.023	5.133	6.58	59.000	98.000	
2024-133	4	AB- CELL-D	100	ABB.RUBY	53	75.824	5.257	6.93	57.000	95.000	
2024-133	4	AB- CELL-D	100	ABB.RUBY	53	86.667	6.549	7.56	65.000	108.000	
2024-133	5	BECTON D	83	B.C600,800	61	86.656	2.787	3.22	65.000	108.000	
2024-133	6	MR Mindray	91	BC-5390	60	52.627	3.303	6.28	39.000	66.000	
2024-133	8	3 ST	31	ABBOTT C-D	21	190.190	29.144	15.32	143.000	238.000	
2024-133	8	3 ST	84	KX21,300	16	208.750	10.592	5.07	157.000	261.000	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 134 PLATELET COUNT NEW							
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-133	9 3 D	68	COULTERAcT	10	291.000	18.319	6.30	218.000	364.000		
2024-133	10 DxH	94	BC DXH 500	83	245.390	13.120	5.35	184.000	307.000		
553 PLATELET COUNT				CLIA TEST ID #: 815 EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-134	1 SYSMEX CBC	79	SYSMEX XS	130	210.858	13.750	6.52	158.000	264.000		
2024-134	1 SYSMEX CBC	87	SYSMEX XN	51	216.627	8.279	3.82	162.000	271.000		
2024-134	1 SYSMEX CBC	98	SYSMEX 350	198	217.160	7.953	3.66	163.000	271.000		
2024-134	2 ACT5 PENTR	73	COULTER AC	91	441.100	15.779	3.58	331.000	551.000		
2024-134	2 ACT5 PENTR	78	ABX PENTRA	30	428.933	11.054	2.58	322.000	536.000		
2024-134	3 ADVIA 120	64	ADVIA-120	17	443.647	30.946	6.98	333.000	555.000		
2024-134	4 AB- CELL-D	63	ABBOTT C-D	44	250.045	14.802	5.92	188.000	313.000		
2024-134	4 AB- CELL-D	100	ABB.RUBY	53	254.000	12.944	5.10	191.000	318.000		
2024-134	4 AB- CELL-D	100	ABB.RUBY	53	252.308	12.113	4.80	189.000	315.000		
2024-134	5 BECTON D	83	B.C600,800	61	264.567	8.578	3.24	198.000	331.000		
2024-134	6 MR Mindray	91	BC-5390	60	260.051	9.445	3.63	195.000	325.000		
2024-134	8 3 ST	31	ABBOTT C-D	21	360.333	64.775	17.98	270.000	450.000		
2024-134	8 3 ST	84	KX21,300	16	392.563	16.774	4.27	294.000	491.000		
2024-134	9 3 D	68	COULTERAcT	10	598.500	30.823	5.15	449.000	748.000		
2024-134	10 DxH	94	BC DXH 500	83	483.463	19.497	4.03	363.000	604.000		
2024-135	1 SYSMEX CBC	79	SYSMEX XS	130	374.095	25.998	6.95	281.000	468.000		
2024-135	1 SYSMEX CBC	87	SYSMEX XN	51	406.620	12.828	3.15	305.000	508.000		
2024-135	1 SYSMEX CBC	98	SYSMEX 350	198	404.016	16.747	4.15	303.000	505.000		
2024-135	2 ACT5 PENTR	73	COULTER AC	91	227.407	10.030	4.41	171.000	284.000		
2024-135	2 ACT5 PENTR	78	ABX PENTRA	30	223.067	7.806	3.50	167.000	279.000		
2024-135	3 ADVIA 120	64	ADVIA-120	17	227.176	15.753	6.93	170.000	284.000		
2024-135	4 AB- CELL-D	63	ABBOTT C-D	44	478.955	25.458	5.32	359.000	599.000		
2024-135	4 AB- CELL-D	100	ABB.RUBY	53	484.577	27.807	5.74	363.000	606.000		
2024-135	4 AB- CELL-D	100	ABB.RUBY	53	460.889	15.927	3.46	346.000	576.000		
2024-135	5 BECTON D	83	B.C600,800	61	471.983	13.075	2.77	354.000	590.000		
2024-135	6 MR Mindray	91	BC-5390	60	529.678	19.388	3.66	397.000	662.000		

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPEC: 20 HEMATOLOGY                      SUB: 70 GENERAL    GRP: 134 PLATELET COUNT NEW

ANALYTE											
SAMPLE	METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-135	8    3 ST	31	ABBOTT C-D		21	194.762	29.217	15.00	146.000	243.000	
2024-135	8    3 ST	84	KX21,300		16	204.313	9.583	4.69	153.000	255.000	
2024-135	9    3 D	68	COULTERACT		10	81.100	5.594	6.90	61.000	101.000	
2024-135	10   DxH	94	BC DXH 500		83	247.622	12.057	4.87	186.000	310.000	

SPEC: 20 HEMATOLOGY                      SUB: 75 BODY FLUID    GRP: 145 BODY FLUID CELL COU.

ANALYTE											
SAMPLE	METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
159	BF RED CELL COUNT	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}							
	2024-171				41	1057.475	115.916	10.96	710.000	1405.000	
	2024-172				41	0.475	0.707	148.77	0	3.000	
	2024-173				41	0.525	0.670	127.69	0	3.000	
	2024-174				41	1057.875	122.517	11.58	690.000	1425.000	
	2024-175				41	1036.600	76.145	7.35	777.000	1296.000	
160	BF WHITE CELL COUNT										
	2024-171				40	282.359	30.860	10.93	190.000	375.000	
	2024-172				40	4.675	1.618	34.62	0.000	10.000	
	2024-173				40	4.850	2.242	46.23	0	12.000	
	2024-174				40	283.410	37.536	13.24	171.000	396.000	



**Participant Summary**

**MONTH 3 OF YEAR 2024**

ANALYTE		NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	LABS	VALUE	DEVIATION	CV	LOW	HIGH
160 BF WHITE CELL COUNT							
2024-175		40	280.769	28.045	9.99	197.000	365.000

TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS	
083 ABO GROUP											
2024-181				008 008	008 008		008 - O	78	78	78	100
2024-182				008 008	008 008		008 - O	78	78	78	100
2024-183				004 004	004 004		004 - B	78	78	78	100
2024-184				001 003	001 003		001 - A	78	76	78	100
2024-184				001 003	001 003		002 - A1	78	2	78	100
2024-185				005 007	005 007		005 - AB	78	76	78	100
2024-185				005 007	005 007		006 - A1B	78	2	78	100
126 RH TYPE											
2024-181				001 003	001 003		001 - Rh+	78	78	78	100
2024-182				003 004	003 004		003 - Rh-Du np	78	7	78	100
2024-182				003 004	003 004		004 - Rh-	78	71	78	100
2024-183				003 004	003 004		003 - Rh-Du np	78	7	78	100
2024-183				003 004	003 004		004 - Rh-	78	71	78	100

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY				SUB: 80 ABO-RH				GRP: 150 ABO-RH			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
126 RH TYPE											
2024-184				001 003	001 003		001 - Rh+	78	78	78	100
2024-185				003 004	003 004		003 - Rh-Du np	78	7	78	100
2024-185				003 004	003 004		004 - Rh-	78	71	78	100
SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 160 Indirect COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
084 INDIRECT COOMBS											
2024-191				001 001	001 001		001 - NEGATIVE	63	63	63	100
2024-192				002 002	002 002		002 - POSITIVE	63	63	63	100
2024-193				001 001	001 001		001 - NEGATIVE	63	63	63	100
2024-194				002 002	002 002		001 - NEGATIVE	63	1	62	0
2024-194				002 002	002 002		002 - POSITIVE	63	62	62	100
2024-195				001 001	001 001		001 - NEGATIVE	63	63	63	100
SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2024-271	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	15	15	15	100
2024-271	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100
2024-271	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	12	12	12	100
2024-271	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	15	15	15	100
2024-272	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	15	15	15	100
2024-272	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100
2024-272	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	12	12	12	100
2024-272	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	15	15	15	100
2024-273	001 Poly AHG	001 Gel				002 004	003 - 3+	15	8	15	100
2024-273	001 Poly AHG	001 Gel				002 004	004 - 4+	15	7	15	100
2024-273	001 Poly AHG	002 Tubo				002 004	001 - Negativo	32	1	31	0
2024-273	001 Poly AHG	002 Tubo				002 004	002 - 2+	32	24	31	100
2024-273	001 Poly AHG	002 Tubo				002 004	003 - 3+	32	5	31	100
2024-273	001 Poly AHG	002 Tubo				002 004	004 - 4+	32	2	31	100
2024-273	002 MnoAnt-IgG	001 Gel				002 004	003 - 3+	12	6	12	100
2024-273	002 MnoAnt-IgG	001 Gel				002 004	004 - 4+	12	6	12	100
2024-273	002 MnoAnt-IgG	002 Tubo		002 004			002 - 2+	15	13	15	100
2024-273	002 MnoAnt-IgG	002 Tubo		002 004			003 - 3+	15	2	15	100
2024-274	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	15	15	15	100
2024-274	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100
2024-274	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	12	12	12	100
2024-274	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	15	15	15	100
2024-275	001 Poly AHG	001 Gel				002 004	002 - 2+	15	1	15	100

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS			GRP: 165 Direct COOMBS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-275	001 Poly AHG	001 Gel				002 004	003 - 3+	15	8	15	100	
2024-275	001 Poly AHG	001 Gel				002 004	004 - 4+	15	6	15	100	
2024-275	001 Poly AHG	002 Tubo				002 004	001 - Negativo	32	1	31	0	
2024-275	001 Poly AHG	002 Tubo				002 004	002 - 2+	32	24	31	100	
2024-275	001 Poly AHG	002 Tubo				002 004	003 - 3+	32	5	31	100	
2024-275	001 Poly AHG	002 Tubo				002 004	004 - 4+	32	2	31	100	
2024-275	002 MnoAnt-IgG	001 Gel				002 004	003 - 3+	12	6	12	100	
2024-275	002 MnoAnt-IgG	001 Gel				002 004	004 - 4+	12	6	12	100	
2024-275	002 MnoAnt-IgG	002 Tubo		002	004	002 004	002 - 2+	15	14	15	100	
2024-275	002 MnoAnt-IgG	002 Tubo		002	004	002 004	003 - 3+	15	1	15	100	

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY												SUB: 100 COMPATIBILITY TESTING				GRP: 170 COMPATIBILITY TEST.			
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score								
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS									
085 COMPATIBIL. TESTING																			
2024-201				001	001	001	001	001 - COMPATIBLE	39	39	39	100							
2024-202				002	002	002	002	002 - INCOMPATIB	39	39	39	100							
2024-203				001	001	001	001	001 - COMPATIBLE	39	39	39	100							
2024-204				002	002	002	002	002 - INCOMPATIB	39	39	39	100							
2024-205				001	001	001	001	001 - COMPATIBLE	39	39	39	100							

**Participant Summary**

**MONTH 3 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY		SUB: 110 ANTIBODY IDENTIFICATION				GRP: 180 ANTIBODY IDENT.					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS	# LABS ANSW	# "SF" LABS	Score
086 ANTIBODY IDENT.TEST.											
2024-201				001 001	001 001		001 - UN. ANT.ND	10	10	10	100
2024-202				019 019	019 019		019 - Anti Fy b	10	10	10	100
2024-203				001 001	001 001		001 - UN. ANT.ND	10	10	10	100
2024-204				006 006	006 006		006 - Anti c	10	10	10	100
2024-205				001 001	001 001		001 - UN. ANT.ND	10	10	10	100